# HIFI Pan-Cancer Screening (Berry Oncology)

Source: https://onco.cc/drugs/hifi-pan-cancer-screening/  
OnCo record `hifi-pan-cancer-screening` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Berry Oncology's blood test for six cancers common in China, launched in 2022; its accuracy figures are the company's own and no peer-reviewed multi-cancer paper was found.

## Summary

Berry Oncology, of Beijing, announced on 23 June 2022 the launch of HIFI Pan-Cancer Screening, a one-time screening product for lung, oesophageal, gastric, liver, pancreatic and colorectal cancer, which it describes as the first multi-cancer screening product built on whole-genome sequencing of cell-free DNA. Its figures, first given in a company release of 13 October 2021 without sample sizes, are 87.6% sensitivity, 99.1% specificity and tissue of origin correct in 82% of positive cancers, with 69.6% sensitivity at stage I and 92.9% at stage II. These are company statements: no peer-reviewed paper reporting them was found (Berry Oncology's published cell-free DNA work found by this census is on single cancers: liver, pancreatic, oesophageal and nasopharyngeal). No NMPA registration, current availability or price was found.

## Fields

- Kind: Test
- Status: emerging
- Last checked: 2026-11-03
- Tags: test; mced; evidence:insufficient
- Brand: HIFI
- Modality: Multi-cancer early detection blood test (whole-genome sequencing of cell-free DNA)
- Mechanism: Whole-genome sequencing of cell-free DNA (Berry Oncology's HIFI method) read by machine learning, with a predicted tissue of origin.

## Notes

- Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.
- Every accuracy figure is the company's, from releases without cohort sizes.
- What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening).

## Sources

- Berry Oncology: research results on multi-cancer screening (13 October 2021): https://kyodonewsprwire.jp/release/202110141615
- Berry Oncology launch release, as reprinted (23 June 2022): https://www.1stoncology.com/blog/?p=75600

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- companies: [Berry Oncology](https://onco.cc/companies/berry-oncology/)

---
JSON: https://onco.cc/api/v1/entities/hifi-pan-cancer-screening.json